Skip to main content

Table 1 Patient characteristics

From: Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling

  NSCLC patients
(n = 27)
Age, years  
   Median 53
   Range 35-67
Sex, n (%)  
   Male 15 (55.6)
   Female 12 (44.4)
Stage, n (%)  
   IIIB 5 (18.5)
   IV 22 (81.5)
Histology, n (%)  
   Squamous cell carcinoma 6 (22.2)
   Adenocarcinoma 12 (44.4)
   Adenosquamous cell carcinoma 2 (7.4)
   Undifferentiated non-small cell carcinoma 7 (25.9)
Karnofski performance status, n (%)  
   70 4 (14.8)
   80 10 (37.0)
   90 8 (29.6)
   100 5 (18.5)
Smoking history, n (%)  
   No 1 (3.7)
   Current or former 26 (96.3)
RECIST, n (%)  
   Partial response 9 (33.3)
   Stable disease 15 (55.6)
   Progressive disease 3 (11.1)
Survival, days  
   Median progression-free survival 152
   Median overall survival 315